Alpha5 nicotine acetylcholine receptor subunit promotes intrahepatic cholangiocarcinoma metastasis

Yan Fu,Keyu Shen,Hao Wang,Shun Wang,Xufeng Wang,Le Zhu,Yan Zheng,Tiantian Zou,Hongfei Ci,Qiongzhu Dong,Lun-Xiu Qin
DOI: https://doi.org/10.1038/s41392-024-01761-z
IF: 39.3
2024-03-08
Signal Transduction and Targeted Therapy
Abstract:Neurotransmitter-initiated signaling pathway were reported to play an important role in regulating the malignant phenotype of tumor cells. Cancer cells could exhibit a "neural addiction" property and build up local nerve networks to achieve an enhanced neurotransmitter-initiated signaling through nerve growth factor-mediated axonogenesis. Targeting the dysregulated nervous systems might represent a novel strategy for cancer treatment. However, whether intrahepatic cholangiocarcinoma (ICC) could build its own nerve networks and the role of neurotransmitters in the progression ICC remains largely unknown. Immunofluorescence staining and Enzyme-linked immunosorbent assay suggested that ICC cells and the infiltrated nerves could generate a tumor microenvironment rich in acetylcholine that promotes ICC metastasis by inducing epithelial-mesenchymal transition (EMT). Acetylcholine promoted ICC metastasis through interacting with its receptor, alpha 5 nicotine acetylcholine receptor subunits (CHRNA5). Furthermore, acetylcholine/CHRNA5 axis activated GSK3β/β-catenin signaling pathway partially through the influx of Ca 2+ -mediated activation of Ca/calmodulin-dependent protein kinases (CAMKII). In addition, acetylcholine signaling activation also expanded nerve infiltration through increasing the expression of Brain-Derived Neurotrophic Factor (BDNF), which formed a feedforward acetylcholine-BDNF axis to promote ICC progression. KN93, a small-molecule inhibitor of CAMKII, significantly inhibited the migration and enhanced the sensitivity to gemcitabine of ICC cells. Above all, Acetylcholine/CHRNA5 axis increased the expression of β-catenin to promote the metastasis and resistance to gemcitabine of ICC via CAMKII/GSK3β signaling, and the CAMKII inhibitor KN93 may be an effective therapeutic strategy for combating ICC metastasis.
biochemistry & molecular biology,cell biology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore the mechanism of action of the neurotransmitter acetylcholine and its receptor CHRNA5 in the metastasis of intrahepatic cholangiocarcinoma (ICC). Specifically, the researchers focused on the following aspects: 1. **The role of acetylcholine in ICC metastasis**: The study found that acetylcholine promotes the metastasis of ICC by inducing epithelial - mesenchymal transition (EMT). Acetylcholine can be derived from peripheral nerves or synthesized by tumor cells themselves. 2. **The role of the CHRNA5 receptor**: CHRNA5 is a subtype of the acetylcholine receptor. The study found that it is highly expressed in ICC cells and is closely related to the malignant phenotype of ICC. The expression level of CHRNA5 is significantly correlated with tumor size, lymph node metastasis, TNM staging, and serum alanine aminotransferase (ALT) level, and the survival time of ICC patients with high CHRNA5 expression is significantly shortened. 3. **Analysis of signal pathways**: The study further revealed that the acetylcholine/CHRNA5 axis activates Ca²⁺/CaM - dependent protein kinase (CAMKII), thereby inhibiting the activity of GSK3β, stabilizing β - catenin protein, and thus promoting the metastasis of ICC and resistance to gemcitabine. In addition, the acetylcholine/CHRNA5 axis also up - regulates the expression of brain - derived neurotrophic factor (BDNF), induces axonogenesis, and forms a positive - feedback loop, further promoting the progression of ICC. 4. **Potential treatment strategies**: The study also tested the effect of the CAMKII inhibitor KN93 on the migration ability of ICC cells and gemcitabine sensitivity. The results showed that KN93 significantly inhibited the migration ability of ICC cells and enhanced their sensitivity to gemcitabine, suggesting that CAMKII inhibitors may become a new strategy for treating ICC. In summary, this paper aims to reveal the specific mechanism of action of acetylcholine and its receptor CHRNA5 in ICC metastasis and explore potential treatment targets.